Will Insmed's quarterly operating cash burn stay below $300M in Q1 and Q2 2026?

FY2025 average quarterly operating cash outflow was ~$320M. BRINSUPRI revenue ramp should offset a meaningful portion of this burn. Combined product revenue (BRINSUPRI + ARIKAYCE) approaching $280-300M per quarter would reduce net operating outflow below $300M if opex growth stabilizes. The resolution requires BOTH Q1 AND Q2 to be below $300M, adding stringency. Q1 may be harder (deductible resets reduce revenue) while Q2 should improve.

The key risk is that FY2025 burn INCREASED year-over-year despite ARIKAYCE revenue growth. This pattern suggests opex growth (clinical trials, sales force, manufacturing) was absorbing revenue gains. If this continues in H1 2026, BRINSUPRI revenue ramp alone may not reduce burn below $300M. However, the magnitude of BRINSUPRI revenue ($200M+ per quarter) is a step change from ARIKAYCE incremental growth, which should create leverage.

Management's claim of achieving 'cash flow positivity without additional capital' requires burn to decline. If management believes this trajectory is achievable, H1 2026 should show meaningful improvement from the $320M quarterly average. The zero-insider-selling signal reinforces management confidence. The BRINSUPRI launch investment (sales force build) should be largely complete, allowing operating leverage to emerge.

The dual-quarter requirement makes this harder than a single-quarter assessment. Q1 faces revenue headwinds from deductible resets while maintaining full opex levels. Even if Q2 shows improvement, a Q1 burn of $305-310M would resolve the market NO. The probability is approximately a coin-flip reflecting genuine uncertainty about Q1 timing.

The ENCORE and TPIP/PALM-PAH clinical programs represent ongoing cash commitments. Contingent consideration payments to AstraZeneca add periodic cash outflows. Manufacturing scale-up for BRINSUPRI may create lumpy expenses in H1 2026. These non-revenue items could keep burn elevated even as product revenue grows. The $300M threshold may be too tight for Q1.

On balance, the BRINSUPRI revenue step-change ($200M+ per quarter vs. incremental ARIKAYCE growth) should be sufficient to push burn below $300M in at least one of the two quarters. The question is whether it does so in BOTH. If Q1 is borderline ($295-305M), the resolution depends on accounting timing of cash flows. Slight edge to YES based on the magnitude of the revenue change.

BRINSUPRI revenue ramp should progressively reduce burn. The question is timing — Q1 may still be above $300M with Q2 improving. Dual-quarter requirement creates risk. Slightly above coin-flip.

FY2025 burn increased despite revenue growth, suggesting opex growth is aggressive. Q1 deductible resets will reduce revenue while maintaining full costs. The $300M threshold may be too tight for Q1. Slightly below coin-flip.

Genuine uncertainty about whether the BRINSUPRI revenue inflection is sufficient to overcome ongoing opex growth and clinical spending in both Q1 and Q2. Coin-flip assessment.